Post by littlestevie on Apr 14, 2016 7:09:58 GMT -5
I don't know if some of you went through the posters published yesterday by Arrowhead, but I have a question regarding the posters "Predicting HBsAg clearance responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg epitope profile analysis".
I really don't get the figure "HBsAG CP (baseline vs on-therapy)" figure. Why in the "baseline" box there is already 18/40 patients with a clearance profile? Does it mean that about half of the patients have already a clearance profile before the ARC-520 treatment (is due to due to entecavir)? In this case why the number of patients with a clearance profile treated with placebo decrease in the "on therapy" box?
I would really appreciate if someone could help me understand this figure, I am clearly missing something to get it right.
Also in connection with this poster, while looking for information reagrding the "19plex HBsAg epitope mapping assay", I came across this presentation by Pr. Locarnini (who is the senior author on the poster): www.informedhorizons.com/hepdart2015/pdf/Presentations/Locarnini.pdf
It shows that the data from this poster where already presented in December 2015 at the Hep DART conference (see slide 23). I don't know why there were not released sooner. Interestingly there is also a graph regarding the Anti-HB (see slide 28). As stated in the posted significance is not reached.
Jeff
I really don't get the figure "HBsAG CP (baseline vs on-therapy)" figure. Why in the "baseline" box there is already 18/40 patients with a clearance profile? Does it mean that about half of the patients have already a clearance profile before the ARC-520 treatment (is due to due to entecavir)? In this case why the number of patients with a clearance profile treated with placebo decrease in the "on therapy" box?
I would really appreciate if someone could help me understand this figure, I am clearly missing something to get it right.
Also in connection with this poster, while looking for information reagrding the "19plex HBsAg epitope mapping assay", I came across this presentation by Pr. Locarnini (who is the senior author on the poster): www.informedhorizons.com/hepdart2015/pdf/Presentations/Locarnini.pdf
It shows that the data from this poster where already presented in December 2015 at the Hep DART conference (see slide 23). I don't know why there were not released sooner. Interestingly there is also a graph regarding the Anti-HB (see slide 28). As stated in the posted significance is not reached.
Jeff